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TITLE OF CASE  
Clinical spirocercosis in a dog in the UK 
SUMMARY  
A 2-year-old female neutered crossbreed dog was presented for evaluation of a three-day 
history of haematemesis, melaena and hyporexia. The dog had been imported from a rescue 
centre in Hungary four months prior to presentation. Abdominal computed tomography 
revealed the presence of a 3cm X 3cm X4cm diameter heterogenous intraluminal mass 
lesion in the gastric cardia, surrounding the ostium of the cardia and continuous with the 
distal oesophagus. The mass lesion was subsequently surgically resected. Histopathology of 
the gastric mass lesion was consistent with a Spirocerca lupi granuloma. The patient 
unfortunately developed a pyothorax and underwent cardiopulmonary arrest resulting in 
death two days post-operatively. To the authors’ knowledge, this is the first reported case of 
clinical spirocercosis reported in a dog in the UK. 
BACKGROUND  
Spirocercosis is a serious disease of canids caused by the nematode Spirocerca lupi. 
Infection is associated with the development of granulomatous nodules in the oesophagus, 
which may later transform into sarcomas.1,2 Spirocercosis has also been associated with 
other serious disease syndromes such as aortic aneurysm, spondylitis and pyothorax.3,4  
 
Evidence of canine S. lupi infection was recently reported in the UK for the first time in a dog 
receiving food imported from Germany.5 However, to the authors’ knowledge, no cases of 
canine spirocercosis associated with clinical signs have been previously reported in the UK. 
We describe the first reported case of clinical spirocercosis in a dog in the UK.  
CASE PRESENTATION  
A 2-year-old female neutered crossbreed dog was presented to the Internal Medicine service 
of the Queen Mother Hospital for Animals (Royal Veterinary College) for investigation of a 
three-day history of lethargy, haematemesis, melaena and hyporexia. Diagnostics performed 
prior to referral included a packed cell volume (PCV) of 30% with total protein concentration 
of 48g/l, an Angiostrongylus vasorum SNAP test (negative) and measurement of prothrombin 
(PT) and activated partial thromboplastin (aPTT) times, both of which were within reference 
intervals.  
 
The patient had been imported from a rescue centre in Hungary four months prior to 
presentation. The patient was receiving monthly endoparasite preventative treatment with 
oral milbemycin oxime and had no prior significant medical history to the owner’s knowledge. 
 
On physical examination the patient had pale pink mucus membranes with a normal capillary 
refill time. Heart rate, respiratory rate and rectal temperature were within normal limits. 
Melaena was detected on rectal examination. The patient’s body condition score was 5/9. 
Examination was otherwise unremarkable.  
INVESTIGATIONS  
Significant haematological findings included a moderate regenerative anaemia [packed cell 
volume 25%, reference interval (RI) 37-55%, absolute reticulocyte concentration 146.7 
X10⁹/L, RI >60.0 X10⁹/L] and mild mature neutrophilia [14.41 X10⁹/L, RI 3.00-11.50 X10⁹/L] 
with mild toxicity. Significant biochemical abnormalities included a moderate 
hypoalbuminemia [19.6g/l, RI 28.0-39.0g/l] with associated mild total hypocalcaemia [2.10 
mmol/l, RI 2.13-2.70mmol/l]. Urinalysis (on a cystocentesis sample) revealed a urine specific 
gravity of 1.020 with an inactive sediment examination. Abdominal radiography was within 
normal limits with no evidence of a gastrointestinal foreign body or mechanical obstruction. 
Subsequent abdominal ultrasonography was also unremarkable. ACTH stimulation testing was 
not consistent with hypoadrenocorticism, serum cobalamin concentration was normal 
[653ng/l, RI >200ng/l] and SNAP4Dx serology was negative for Ehrlichia, Anaplasma, 
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Dirofilaria and Borrelia burgdorferi. Faecal Baermann and floatation examinations were 
negative for gastrointestinal parasites and a bile acid stimulation test showed no evidence of 
hepatic dysfunction. The patient was hospitalised and treated supportively for possible acute 
gastroenteritis with intravenous fluid therapy, anti-emetic therapy (maropitant 1mg/kg PO 
SID) and gastroprotectants (omeprazole 1mg/kg PO BID and sucralfate 500mg/dog PO TID). 
All clinical signs resolved within a few days and the patient was discharged with instructions 
to continue omeprazole and sucralfate, in addition to a 5-day course of fenbendazole (50mg/kg 
PO SID) to treat for possible occult gastrointestinal parasitism. 
 
Upon re-examination three weeks later, the patient’s clinical signs remained controlled, 
however repeat haematology revealed persistence of anaemia [haematocrit 30.5%, RI 37.0-
55.0%], with a significant decrease in mean corpuscular volume (MCV) since previous 
haematology (decrease from 79.5fL to 62.0fL, RI 60.0-70.0fL). Repeat abdominal 
ultrasonography revealed a 3.3cm diameter hypoechoic mass lesion in the gastric fundus 
(figure 1). There was regional gastric wall thickening (up to 0.6cm diameter) with associated 
loss of normal wall layering. A connection between the mass lesion and the gastric wall could 
not be established. 
 
Due to a high index of suspicion for gastric neoplasia, computed tomography (CT) of the thorax 
and abdomen was performed to further characterise the mass lesion and screen for evidence 
of metastasis. CT demonstrated the previously documented gastric mass lesion measured 3cm 
X 4cm x 4cm, was intramural and originated from the gastric cardia (figure 2). It was 
contiguous with the distal oesophagus which was eccentrically thickened. The thoracic 
oesophagus and remainder of the stomach appeared normal. The splenic lymph nodes were 
rounded and enlarged (up to 1.3cm diameter) while the sternal lymph nodes were mildly 
enlarged (up to 1cm diameter). The lungs were normal. The deep location of the gastric mass 
lesion and splenic lymph nodes precluded fine needle aspiration. 
 
DIFFERENTIAL DIAGNOSIS  
Differential diagnoses for the gastric mass lesion included benign (leiomyoma) and malignant 
(leiomyosarcoma, adenocarcinoma, lymphoma) gastric neoplasia. Non-neoplastic disease 




The patient underwent exploratory laparotomy to resect the gastric mass lesion. The mass 
lesion was challenging to remove due to it being contiguous with the distal oesophagus for 
several centimetres orally. It was resected via a partial gastrectomy and partial 
oesophagectomy (by submucosal resection). During resection multiple live worms were 
visualised emerging from the main body of the mass lesion, (figures 3 and 4). A gastrotomy 
tube was placed to facilitate post-operative enteral nutrition due to some narrowing of the 
distal oesophagus being created. No intra-operative or immediate post-operative 
complications were encountered.  
 
OUTCOME AND FOLLOW-UP   
Histopathology of the gastric mass lesion showed severe, transmural, chronic-active, 
eosinophilic, neutrophilic, and histiocytic gastritis with multiple granulomas associated with 
intralesional larvae (figure 5). The worms present within the mass lesion were examined by a 
diplomate of the European College of Veterinary Parasitology (MF), who concluded they were 
consistent with Spirocerca spp. Although it is not possible to grossly distinguish S. lupi from 
S. arctica (another Spirocerca spp. that has been detected in canids in Europe), the patient’s 
clinical findings and travel history were consistent with S. lupi infection. 
 
On diagnosis of spirocercosis, review of the patient’s thoracic and abdominal CT was requested 
to screen for further lesions commonly associated with spirocercosis including thoracic 
spondylitis, aortic lesions and oesophageal nodules. Following review, a focal thickening of the 
oesophagus at the level of the left atrium, measuring approximately 1.1cm in width and 
extending approximately 4.1cm along the length of the oesophagus, was noted (figure 6). No 
additional thoracic or aortic lesions were detected. Given the presence of oesophageal 
thickening, possibly representing the presence of another S. lupi granuloma, it was decided to 
administer topical Advocate® (10% imidacloprid and 2.5% moxidectin). 
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The patient was hospitalised on intravenous fluid therapy and analgesia post-operatively. 
Unfortunately two days post-operatively, the patient became acutely dyspnoeic. Thoracic 
ultrasound revealed the development of a moderate volume of pleural effusion bilaterally. No 
peritoneal effusion was detected. Supplemental oxygen therapy was initiated and 
thoracocentesis performed for diagnostic and therapeutic purposes. Analysis of the pleural 
fluid was consistent with a septic exudate. Unfortunately, the patient underwent sudden 
cardiopulmonary arrest. Cardiopulmonary resuscitation was initiated, but subsequently 
discontinued following discussion with the patient’s owner.  Post-mortem examination was not 
performed per the owner’s wishes.  
DISCUSSION  
To the authors’ knowledge this is the first case of clinical spirocercosis to be reported in the 
UK. While evidence of canine S. lupi infection was recently reported in the UK for the first time 
in a dog receiving food imported from Germany,5 this was based on the detection of S. lupi 
eggs on faecal examination and to the authors’ knowledge was not associated with any clinical 
signs.  
Due to the historically low prevalence of spirocercosis in parts of Europe frequented by UK 
holidaymakers, S. lupi has not previously been regarded as a significant pathogen for dogs 
travelling between the UK and continental Europe. Whilst traditionally regarded as a parasite 
of tropical and subtropical regions,4,6 in recent years cases have been increasingly reported in 
continental Europe. The parasite appears to have a relatively high prevalence in Greece7 and 
isolated cases have recently been reported from Spain, France and Italy.8,9 The dog in this 
case was imported from a rescue centre in Hungary, a country where S. lupi has also 
increasingly been reported.10 A similar case of S. lupi infection associated with importation of 
a dog from Hungary was recently reported in Germany.11 Should cases of spirocercosis 
continue to be recorded in regions frequented by UK tourists and their dogs travelling on the 
Pet Travel Scheme (PETS), chemoprophylaxis and other preventative measures against S.lupi 
are advised. Additionally, in an era of widespread importation of dogs to the UK from parts of 
continental Europe with high or increasing prevalence of spirocercosis, clinicians in the UK 
must be vigilant for clinical signs of S. lupi infection in this population of dogs.   
The dog in this case developed clinical spirocercosis 4 months after importation to the UK 
despite being on monthly oral milbemycin oxime therapy for endoparasite prevention. Clinical 
signs of spirocercosis are generally associated with the formation of oesophageal nodules 
caused by adult worms and the prepatent period of infection is generally 4-6 months.12 It is 
therefore likely that this patient acquired the infection while in Hungary and was in the 
prepatent phase of infection at the time of importation to the UK. While milbemycin oxime has 
been demonstrated to have some efficacy against S. lupi,13-15 milbemycin does not provide 
complete protection against infection or the development of disease.15 Although various 
protocols of milbemycin oxime and doramectin administration to treat spirocercosis have been 
described,3,13-17 we opted to treat our patient with Advocate® (10% imidacloprid and 2.5% 
moxidectin) post-operatively due to a combination of factors including lack of availability of 
doramectin, the patient’s history of developing spirocercosis despite milbemycin oxime 
therapy and published efficacy of Advocate® for treating spirocercosis.18,19 
The presentation of spirocercosis in this patient was unusual. Common clinical features 
associated with spirocercosis, including the presence of eggs on faecal floatation and thoracic 
vertebral lesions and aortic lesions on CT,3,4 were not detected in this patient. S. lupi nodules 
that have not undergone neoplastic transformation may regress with appropriate medical 
treatment. Surgery is usually reserved for cases where nodules have undergone neoplastic 
transformation, due to the significant rates of post-surgical complications reported following 
resection of S. lupi oesophageal granulomas.20,21 In this patient, the decision was made to 
proceed with surgery given the high index of suspicion for neoplasia and lack of other 
diagnostic abnormalities suggestive of spirocercosis. The option of pre-surgical upper 
gastrointestinal endoscopy was considered in this case, but ultimately not performed due to 
financial constraints. It is possible that upper gastrointestinal endoscopy could have obtained 
a diagnosis in this case, which may have changed the decision to pursue surgical versus 
medical treatment. However, it is also possible that a diagnosis may not have been obtained 
endoscopically or that endoscopic biopsies of the oesophageal and gastric lesions would not 
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have provided an accurate histopathologic representation of the tissue response (inflammatory 
versus neoplastic) to the parasite. Although thickening of the distal oesophagus was noted 
upon review of the patient’s CT, the thickening was diffuse rather than nodular, and may have 
represented reactive changes rather than an additional S. lupi granuloma. Unfortunately post-
mortem examination was not available to determine if this was the case. Given the non-
specific nature of the distal oesophageal thickening on CT, the authors do not believe the 
clinical decision-making process would have been altered had this finding been available at 
the time of initial CT reporting. 
The cause of cardiopulmonary arrest in this patient remains open. Analysis of the patient’s 
pleural effusion was consistent with a septic exudate, raising concern for development of 
pyothorax. A possible explanation for the development of pyothorax in this patient is that the 
oesophageal lesion detected on CT represented a further S. lupi granuloma that spontaneously 
ruptured. However, the authors also acknowledge that the intracellular bacteria seen on 
cytology of the pleural effusion may have represented contamination rather than a primary 
pyothorax, as the intracellular bacteria were detected upon repeat analysis of the effusion, 
following a previous thoracocentesis. Ultimately, the authors cannot rule out another cause of 
cardiopulmonary arrest (e.g. pulmonary thromboembolism) in the absence of a post-mortem 
examination.   
This case report is of epidemiological significance since we believe this to be the first reported 
case of clinical spirocercosis in a dog in the UK. It demonstrates that S. lupi should be 
considered as a differential diagnosis in dogs with compatible clinical signs if they have a 
history of travel from continental Europe, particularly from countries where cases are most 
frequently reported, such as Hungary and Greece.7,10 In addition, this case is a reminder that 
not all cases of spirocercosis will exhibit characteristic or pathognomonic signs on diagnostic 
tests. 
In conclusion, clinicians in the UK should be vigilant for cases of spirocercosis in dogs with a 
history of travel to continental Europe. Chemoprophylaxis and other preventative measures 
should be considered for dogs travelling to or from areas of high or increasing disease 
prevalence.  
LEARNING POINTS/TAKE HOME MESSAGES  
 Spirocercosis should be considered as a differential diagnosis in dogs with compatible 
clinical signs with a history of travel from continental Europe, especially from countries 
such as Hungary and Greece.  
 Patients receiving monthly milbemycin oxime therapy can still develop clinical 
spirocercosis.  
 In an era of increased foreign travel of dogs and increased importation of dogs to the 
UK, chemoprophylaxis and other preventative measures should be considered for dogs 
travelling to or from the parasite’s range under the Pet Travel Scheme (PETS). 
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FIGURE/VIDEO CAPTIONS  
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Figure 1: Abdominal ultrasound images. On longtitudinal (a) and transverse 
(b) views of the gastric fundus a mass lesion (indicated by arrows) is present. 
The lesion has a heteroechoic parenchymal texture. A connection to the 




Figure 2: Abdominal CT, transverse view. An intramural mass lesion 
(highlighted with white asterix) surrounds the cardiac ostium and protrudes 
into the gastric lumen. (Photo credit: Mark Plested) 
 
 
Figure 3: Photographs of the gastric mass lesion before (a) and after (b) 
resection. (Photo credit: Poppy Bristow) 
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Figure 4: Multiple worms recovered from the gastric mass lesion following 




Figure 5: Histopathology of the gastric mass lesion. The transit between the 
oesophagus (arrows) and the gastric mucosa is extensively ulcerated 
(arrowheads). The submucosa is expanded by fibrosis and exudative 
inflammation. Inset: Two nematode larvae (arrowhead) are surrounded by 




Figure 6: Thoracic CT, transverse view. A focal thickening of the oesophagus 
is present (highlighted with white asterix) at the level of the left atrium. 
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Figure 6: Thoracic CT, transverse view. A focal thickening of the oesophagus 
is present (highlighted with white asterix) at the level of the left atrium. 
(Photo credit: Mark Plested)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
